Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML - Figure f6 | Aging
Uproleselan Added to Cladribine Plus Low-Dose Cytarabine (LDAC) In Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)
AML Hub on Twitter: "CONGRESS | #ASCO20| Andrew Wei, @MonashUni, presents an update on venetoclax ➕ low-dose cytarabine in previously untreated older patients with #AML. Median OS was higher with venetoclax +
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483) | Leukemia
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
Phase I study of F16IL2 antibody–cytokine fusion with very low‐dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation - Schliemann - 2021 - British Journal of Haematology - Wiley Online Library
Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided
PDF) Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Phase II Study of Venetoclax Added to Cladribine (CLAD) and Low Dose AraC (LDAC) Alternating with 5-Azacytidine (AZA) in Older and Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) - ScienceDirect
SciELO - Brasil - Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia Possible benefit of consolidation therapy with high-dose cytarabine on overall
4088-Acute myeloid leukaemia STIMULus (low dose cytarabine and tioguanine) overview | eviQ
![PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7550a5cdc69f479a7aec573d63770ee1c9f77045/5-Figure1-1.png "PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar")
PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar
Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in
Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients - ScienceDirect
TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE | Mediterranean Journal of Hematology and Infectious Diseases
Prevention and Treatment of Cytarabine-Induced Keratoconjunctivitis
A phase I/II study of the combination of quizartinib with azacitidine or low -dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome | Haematologica
Novel immunomodulatory properties of low dose cytarabine entrapped in a mannosylated cationic liposome - ScienceDirect
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial - The Lancet Haematology
Clinical Trial Results with Novel Agents and Regimens for the Treatment of Newly Diagnosed or Relapsed/Refractory AML/MDS, Including in the Elderly | Research To Practice
PDF) Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
![PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7550a5cdc69f479a7aec573d63770ee1c9f77045/6-Figure2-1.png "PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar")
PDF] Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study | Semantic Scholar
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome | Leukemia
